Previous close | 4.59 |
Open | 5.35 |
Bid | 2.47 |
Ask | 7.60 |
Strike | 125.00 |
Expiry date | 2024-08-09 |
Day's range | 5.35 - 5.35 |
Contract range | N/A |
Volume | |
Open interest | 2 |
GSK and CureVac (CVAC) are in the spotlight following a restructuring of their vaccine agreement.
CureVac is also eligible for future royalties. CureVac shares jumped 12% in early trading Wednesday, while GSK’s American depositary receipt slipped 0.2%. Shares of Moderna a leading mRNA vaccine manufacturer, were up 0.9%.
Moderna (MRNA) expects this funding to help support the development of its mRNA-based pre-pandemic vaccine against the H5 influenza virus, which is responsible for causing avian influenza or bird flu.